ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into th ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

The primary endpoint was functional immune tolerance, defined as off all immunosuppressive drugs 24 months after ...

Among 83 patients receiving biologic agents for their underlying conditions and who had serum amyloid-α (AA) amyloidosis affecting the kidneys, from 60% to 88% did not develop end-stage renal ...

In comparative analysis, EchoGo® Amyloidosis outperformed two validated clinical scoring systems, the Transthyretin Cardiac ...

Explore how AI transforms cardiac amyloidosis detection with remarkable accuracy—keep reading to see its clinical potential.

Recurrent lupus nephritis post-transplant may go undetected without surveillance biopsies. This study reveals high recurrence ...

Techcyte is proud to share results from a published pilot study demonstrating the effectiveness of its AI-powered kidney ...